Early and late hematologic toxicity following CD19 CAR-T cells

Bone Marrow Transplantation
Shalev FriedElad Jacoby

Abstract

Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients. The most common adverse events reported are cytokine-release syndrome (CRS), neurotoxicity, and hematologic toxicity. Here, we focus on early and late cytopenia occurring after CD19 CAR-T cells in 38 patients treated with CD19 CAR-T cells. Neutropenia, thrombocytopenia, and anemia occur frequently (94, 80, and 51%, respectively) after CAR-T cell infusion, and are associated with a biphasic nature, as in 93% of patients hematologic toxicity occurs after 21 days from cell infusion. Late hematologic toxicity was more common in patients with high grade CRS and in patients treated after a recent stem cell transplantation. Interestingly, since these events occur late after the lymphodepleting chemotherapy and after resolution of CRS, we found perturbations in SDF-1 levels to correlate with events of late neutropenia, likely associated with B-cell recovery.

References

Mar 5, 2009·American Journal of Hematology·Ron RamPia Raanani
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai WengSandra J Horning
Aug 11, 2011·Blood·Michael B JordanKenneth L McClain
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
May 22, 2016·Blood·Jennifer N Brudno, James N Kochenderfer
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Mar 18, 2017·Blood·Juli-Anne Gardner, Katherine Devitt
Sep 20, 2017·Nature Reviews. Clinical Oncology·Sattva S NeelapuElizabeth J Shpall
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
May 8, 2018·Blood·Alexander I SalterStanley R Riddell
Jul 5, 2018·The New England Journal of Medicine·Carl H June, Michel Sadelain
Dec 29, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Daniel W LeeSattva S Neelapu

❮ Previous
Next ❯

Citations

Nov 23, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ghady HaidarPalash Samanta
May 29, 2020·British Journal of Clinical Pharmacology·Uri GreenbaumElizabeth J Shpall
Jul 29, 2020·Bone Marrow Transplantation·Eugenio GalliCatherine Thieblemont
Feb 6, 2020·Therapeutic Advances in Hematology·Tania Jain, Mark R Litzow
Aug 8, 2020·Blood Cancer Journal·Kitsada WudhikarnMiguel-Angel Perales
Jul 31, 2020·Signal Transduction and Targeted Therapy·Jianshu WeiWeidong Han
Aug 26, 2020·ESMO Open·Lucrecia YáñezMiguel-Angel Perales
Oct 2, 2020·Cellular & Molecular Immunology·Jianshu WeiWeidong Han
Dec 1, 2020·Expert Review of Anti-infective Therapy·Olivia Bupha-IntrBenjamin Teh
Nov 28, 2020·Expert Opinion on Biological Therapy·Natasha Bechman, John Maher
Dec 2, 2020·Frontiers of Medicine·Houli ZhaoHe Huang
Sep 29, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Natalia LaptevaCliona M Rooney
Dec 19, 2020·Journal for Immunotherapy of Cancer·Marcela V MausStephan A Grupp
May 14, 2020·Blood Reviews·Rajat Bansal, Ran Reshef
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick M Reagan, Sattva S Neelapu
Jan 27, 2021·Nature Reviews. Clinical Oncology·Haneen ShalabiNirali N Shah
Jan 10, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Peter DregerUNKNOWN European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Re
Feb 5, 2021·Leukemia & Lymphoma·Peter A RiedellMichael R Bishop
Feb 11, 2021·Leukemia & Lymphoma·Talya Wittmann DayagiAbraham Avigdor
Nov 25, 2020·Cancers·Olaf Penack, Christian Koenecke
Feb 20, 2021·Nature Reviews. Genetics·Gavin I EllisJames L Riley
Feb 26, 2021·Current Hematologic Malignancy Reports·Taha Al-Juhaishi, Sairah Ahmed
Mar 8, 2021·Blood Reviews·Anthony P LonghitanoBenjamin W Teh
Oct 26, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M-L SchubertP Dreger
Apr 3, 2021·Ocular Immunology and Inflammation·Waleed K Alsarhani, Ahmed M Abu El-Asrar
May 19, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Maria-Luisa SchubertPeter Dreger
May 1, 2021·Transplantation and Cellular Therapy·Rajshekhar ChakrabortyNavneet S Majhail

❮ Previous
Next ❯

Software Mentioned

Prism Graphpad

Related Concepts

Related Feeds

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.